Kissei制药与台湾东洋欧化达成"Olutasidenib"许可协议

美股速递
May 01

日本Kissei制药株式会社宣布,已与台湾东洋欧化制药就白血病治疗药物"Olutasidenib"达成独家许可协议。根据协议条款,东洋欧化制药将获得该药物在台湾地区的独家开发和商业化权利。

此次合作标志着Kissei制药在拓展亚洲市场战略布局的重要一步。Olutasidenib作为一种创新靶向药物,在急性髓系白血病治疗领域展现出显著临床潜力。通过本次授权合作,将加速该创新疗法在台湾地区的可及性,为当地患者提供新的治疗选择。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10